The ASX 200 stock market predictions Australia investors rely on are shifting. This week, analysts are flagging three well-known names as potential sells.
Figure 1: ASX 200 companies continue to face changing market conditions and analyst scrutiny [Courtesy: Morningstar]
These are not obscure small-caps. CSL Limited, Northern Star Resources, and Westpac Banking Corporation sit among Australia’s most recognised stocks. Yet leading brokers see meaningful downside from current levels.
When the Big Names Draw Sell Ratings
The ASX 200 strategy Australia investors apply usually centres on blue-chip stability. This week, that logic is being tested.
Peak Asset Management, Baker Young, and Bell Potter have each named one of these three companies as a sell. Their reasoning points to a combination of operational underperformance, weakening macro conditions, and stretched valuations.
CSL Limited: A Biotech Giant Under Pressure
CSL Limited is an Australian-born biotech based out of Melbourne that has built a global footprint that most Australian companies could only dream about. The Company develops and manufactures plasma-derived therapies, vaccines and specialty medicines. It has operations in over 100 countries and has tens of thousands of employees across the globe.
Figure 2: CSL Limited’s global healthcare operations and biotechnology business [Courtesy: AFR]
What the Numbers Show
- Last price: A$112.200 per share
- Market capitalisation: A$55.70 billion
- 52-Week Range: A$90.000 to A$275.790 per share
- P/E ratio: 28.41
- EPS: A$4.092
- Revenue: US$15.55 billion
- Net profit: US$3.00 billion
- Free cash flow yield: 6.14%
- Interim dividend: US$1.300, annual yield 3.66%, ex-date 10 Mar 2026, fully unfranked
Why Analysts Are Cautious
Peak Asset Management rates CSL a sell this week. The CSL Limited share price forecast Australia investors had hoped for has taken a hit.
The Company materially downgraded its fiscal year 2026 outlook. It also flagged around A$5 billion in non-cash pre-tax impairments across fiscal years 2026 and 2027.
Revenue expectations dropped due to normalisation in the US immunoglobulin distribution channel. Softer albumin prices in China have added further pressure. The CSL Vifor acquisition, once a growth pillar, has not delivered what the market expected.
Beyond the Company’s own challenges, the broader environment is not helping. Government healthcare cost pressures and a higher interest rate environment continue to weigh on the biotech sector. The ASX 200 strategy Australia analysts had built around CSL’s premium valuation now looks harder to defend.
Northern Star Resources: Operations Under the Microscope
Northern Star Resources Ltd (ASX: NST) is a top gold producer in Australia. The Company has a strong portfolio of mines and projects in Western Australia and Alaska. It is one of the big players in the ASX gold mining sector.
Figure 3: Northern Star Resources’ mining operations in Australia [Courtesy: Northern Star Resources]
What the Numbers Show
- Last price: A$21.155 per share
- Market capitalisation: A$29.78 billion
- 52-Week Range: A$15.300 to A$31.960 per share
- P/E ratio: 17.88
- EPS: A$1.167
- Revenue: A$6.41 billion
- Net profit: A$1.33 billion
- Free cash flow yield: 10.16%
- Interim dividend of A$0.250 per share, carrying a fully franked annual yield of 2.63%.
Why Analysts Are Cautious
Baker Young has named Northern Star a sell, despite recent optimism around an activist investor entering the picture. US-based Elliott Investment Management has taken a position, generating speculation about potential operational change.
Baker Young is not swayed by that narrative. The broker’s focus stays on the operational track record. Production volumes, cost performance, and capital expenditure requirements have all underperformed relative to expectations.
So, the share price itself reflects this reality. Northern Star fell from A$31.73 a share on 2 Mar to A$21.44 a share on 18 Jun 2026. That is an extraordinary pull-back in a small time frame.
A new management team may reset expectations, but Baker Young believes investors seeking gold exposure should look elsewhere in the ASX mining sector for now.
Westpac Banking Corporation: A Bank Near the Top of Its Range
Westpac is one of Australia’s oldest and best-known banks. The Company is a member of the Big Four – one of the 4 largest banking groups, offering retail, corporate and institutional banking services to retail customers, businesses and institutions, domestically and internationally. It is the second biggest Company on the ASX 200 by market cap. The recent Westpac financial reports showed that the Company is doing financially sound.
Figure 4: Westpac Banking Corporation headquarters in Sydney [Courtesy: Westpac]
What the Numbers Show
- Last price: A$35.010 per share
- Market capitalisation: A$119.74 billion
- 52-Week Range: A$32.380 to A$43.320 per share
- P/E ratio: 17.25
- EPS: A$2.028
- Revenue: A$22.76 billion
- Net profit: A$6.91 billion
- Free cash flow yield: 7.19%
- Interim dividend: A$0.770, fully franked, pay date 26 Jun 2026
Why Analysts Are Cautious
Bell Potter remains bearish on Westpac. The broker sees a troubling mismatch between internal improvement and a worsening external backdrop.
Mortgage applications since the Federal Budget in May have fallen below the prior two quarters. This points to slower housing credit growth heading into next year. Proposed changes to capital gains tax and negative gearing policy have further dented sentiment across the property and lending space.
Bell Potter also sees an earnings downgrade as a real possibility in the near term. With no fresh financial guidance on the table and the stock trading near the upper end of its range, the risk-to-reward calculation looks unfavourable. The ASX 200 strategy Australia analysts had used to justify Westpac’s valuation has less support now.
Impact on Investor Portfolios
The bearish calls across these three names reflect a broader shift in the ASX 200 stock market predictions Australia investors are watching closely. The ASX financial sector faces headwinds from softening credit demand and uncertain policy settings. The healthcare and biotech space is dealing with cost pressures and post-acquisition challenges. Even within the gold sector, operational delivery now matters more than macro tailwinds alone.
For those building an ASX 200 strategy Australia approach around large-cap certainty, this week serves as a reminder. Market capitalisation and brand recognition do not insulate stocks from earnings risk.
ALSO READ: Askari Metals Grows Uis Target Pipeline to Seven New Pegmatites Ahead of RC Drilling
FAQ
Q1. What went wrong with the CSL Vifor acquisition?
Ans. The acquisition has fallen well short of expectations and is now proving a drag on the Company’s wider earnings pressure.
Q2. Why are analysts cautious on Northern Star despite the activist investor news?
Ans. Elliott Investment Management’s entry lifted sentiment, but production volumes, costs, and capital expenditure have all underperformed on the ground.
Q3. What is driving the sell call on Westpac Banking Corporation?
Ans. Mortgage applications have slowed since the May Federal Budget, and the stock is trading near the top of its range with a possible earnings downgrade ahead.
Q4. Should investors avoid all three stocks right now?
Ans. These are broker opinions, not certainties. Each investor should weigh their own risk tolerance before acting on any sell rating.
Disclaimer
This article is intended for informational purposes only. All data referenced in this content is sourced from ASX announcements and publicly available market information. Readers are advised to independently verify all share price and market data before making any investment decisions. Any investment carries risk and should be made at the investor’s own discretion. Colitco does not hold any position in any Company mentioned in this article.
Sources
- https://www.fool.com.au/2026/06/22/why-csl-westpac-and-this-big-name-asx-200-share-could-be-sells/
- https://www.asx.com.au/markets/company/WBC
- https://www.asx.com.au/markets/company/NST
- https://www.asx.com.au/markets/company/CSL
Rachael Jones is an award-winning broadcast journalist, producer, and scriptwriter with over 30 years of experience spanning television, digital media, and financial reporting. She specialises in transforming complex business and finance stories into engaging, accessible content for diverse audiences.
Rachael has expertise in live presenting, reporting, interviewing, sub-editing, and end-to-end content production and has a proven track record of delivering impactful stories across finance news platforms and digital channels. She is passionate about making financial news clear, relevant, and engaging, particularly for younger professional audiences navigating an evolving economic landscape.
Rachael brings extensive experience managing the full production process, from research and scripting through to final delivery. She is also an Authorised ASIC Representative with RG146 accreditation in financial product advice, combining strong journalism skills with a deep understanding of financial markets and investment communication.
